Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10798796			
Filing Date		2004-03-11			
First Named Inventor WAS		SERSCHEID			
Art Unit		1621			
Examiner Name	Chuk	wuma O. Nwaohicha			
Attorney Docket Numb	er	VKSW-1			

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	of cited Document		Releva	ages,Columns,Lines when Relevant Passages or Rele Figures Appear		ant
	1	5994602	B1	1999-1	1-30	Abdul-Sada e	tal.				
If you wisl	h to a	i did additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant Relev			es,Columns,Lines where want Passages or Relev res Appear		
	1										
If you wisl	h to a	dd additional U.S. Publ		,				d button			
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	ion Applicant of cited		vhere Rele	r Relevant	+-
	1										С
If you wisl	h to a	d additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initiatis* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs			

	Application Number		10798796	
INFORMATION DIGGI COURT	Filing Date		2004-03-11	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor WAS		SSERSCHEID	
(Not for submission under 37 CFR 1.99)	Art Unit		1621	
(Not to Submission and of or this say	Examiner Name	Chukwuma O. Nwaohicha		
	Attorney Docket Numb	er	VKSW-1	

	1	Thomas WELTON, "Room Temperature Ionic Liquids: Solvents for Synthesis and Catalysis", Chem. Rev. (1999), vol. 99, pp. 2071-2083.	
	2	Peter WASSERSCHEID, Wilhelm KEIM, Tornic Liquids- New Solutions' for Transition Metal Catalysis, Angew. Chem. Int. Ed. (2000), vol. 39, pp. 3772-3789.	
If you wis	h to a	td additional non-patent literature document citation information please click the Add button Add	

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at <u>winn USPTO GOT</u> or MPEP 901 04. ² Entire office that asseed the document, by the two-letter code (WIPO Standard STS, ³ For <u>Japonese peterl documents</u>, as the disclosion of the year of the eighp of the Emperor must precode the sent annuel of the patent document. Explain languages translation as standards as includated on the document under WIPO document of 11 Februards on Standards and account control WIPO document of 11 Februards on Standards on the document under WIPO document of 11 Februards on Standards on the document under WIPO document of 11 Februards on Standards on the document under WIPO document of 11 Februards on Standards on the document under WIPO docu

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10798796	
Filing Date		2004-03-11	
First Named Inventor	WASSERSCHEID		
Art Unit		1621	
Examiner Name	Chuk	wuma O. Nwaohicha	
Attorney Docket Number		VKSW-1	

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1.98 to	make th	e appro	nriate	selection	(s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to fix the office information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Rick Matos, Ph.D./	Date (YYYY-MM-DD)	2006-09-14
Name/Drint	Digit Mates Dh D	Desistration Number	40 082

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.